Overview

Study to Evaluate Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection.

Status:
Completed

Trial end date:
2015-10-02

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the antiviral effect of repeated oral dosing of JNJ 53718678 compared to placebo in healthy adult participants infected through inoculation with respiratory syncytial virus (RSV)-A Memphis 37b virus.

Phase:

Phase 2

Details

Lead Sponsor:

Janssen Sciences Ireland UC

Treatments:

Antiviral Agents